

News Releases

ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters' Option to Purchase Additional Shares

VANCOUVER, July 21, 2015 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the closing of its initial public offering of 9,315,000 shares of its common stock at a public offering price of \$17.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,215,000 shares of common stock. The shares began trading on The NASDAQ Global Market on July 16, 2015 under the symbol "DNAI." Including proceeds from the sale of the additional shares subject to the underwriters' option, the gross proceeds to ProNAi from the initial public offering were \$158.4 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Jefferies LLC and BofA Merrill Lynch acted as joint book-running managers for the offering. BofA Merrill Lynch also served as ProNAi's Strategic IPO Advisor. Wedbush PacGrow and SunTrust Robinson Humphrey acted as co-managers.

A registration statement relating to these securities was filed with the Securities and Exchange Commission and declared effective on July 15, 2015. The offering was made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, email: Prospectus_Department@Jefferies.com; or from BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, telephone: (866) 500-5408, email: dg.prospectus_requests@baml.com.

All amounts are reported in U.S. dollars.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

SOURCE ProNAi Therapeutics Inc.

For further information: James Smith, Vice President, Corporate Affairs, ProNAi Therapeutics, 604.558.6545, jsmith@pronai.com